Fundraising FoxClarus Ventures — 2016 Investments
7 investments dated 2016 · listed companies and verified rows first · show all
CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases.
BiotechHealthtechLa Jolla, US
Kenneth A. Stauderman(Co-founder)inGonul Velicelebi(Co-founder)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)Michael J. Dunn(Executive Officer)inStephen Bardin(Chief Financial Officer)in
Board seatEmmett Cunningham· per SEC Form D · $80.4M raise · filed Jun 2018
Co-investorsAisling CapitalBering CapitalMESA VERDE VENTURE PARTNERSRevelation PartnersSanderling VenturesOrbiMed
Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy.
BiotechDeep TechHealthtechBoston, US
Steve Petrou(Co-Founder, President of Research & Development)inKiran Reddy(Executive Officer, Director)inMarcio Souza(President & Chief Executive Officer)in
Board seatNicholas GalakatosNicholas G. Galakatos· per SEC Form D · $10M raise · filed Jun 2019
Co-investorsAvoro Capital AdvisorsCapria VenturesOCV PartnersAlameda ResearchAPOLLO PROJECTSBlackstone+6 more
HealthtechMt Olive, US
Louis Altieri(Executive Officer)Larry Heaton(Executive Officer)in
BoardSteven C. Adler(Director)David Jenkins(Director)Donald P. Carson(Director)
Board seatKurt Wheeler· per SEC Form D
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)Marc Schwabish(Executive Officer)inPeter McNamara(Executive Officer)in
Board seatScott Requadt· per SEC Form D · $25M raise · filed Aug 2016
Co-investorsEcoR1 CapitalVida VenturesAlly Bridge GroupFarallon EquitiesPolaris PartnersSoleus Capital
Lumos Pharma is a clinical-stage biopharmaceutical company developing therapies for rare diseases, with a lead candidate targeting Pediatric Growth Hormone Deficiency.
BiotechHealthtechAustin, US
Richard John Hawkins(Executive Officer, Director)John C. McKew(President and Chief Scientific Officer)inPisit "Duke" Pitukcheewanont(Chief Medical Officer)inLori Lawley(Chief Financial Officer)inBrad Powers(Chief Compliance Officer and General Counsel)inCampbell Murray(Executive Chairman)in
Co-investorsNew Enterprise Associates (NEA)Roche Venture FundDeerfield Management CompanySante Health VenturesSante VenturesWellcome Trust
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ESSA PharmaVBI Vaccines Inc/BC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.